What are the recommended genetic testing, surveillance, and management strategies for a patient with Multiple Endocrine Neoplasia type 2 (MEN2)?

MEN2 Syndrome: Genetic Testing, Surveillance, and Management

All patients with suspected or confirmed MEN2 require RET proto-oncogene genetic testing, with management strategies—including timing of prophylactic thyroidectomy, surveillance protocols, and screening intervals—determined by the specific RET mutation risk category (ATA Highest, High, or Moderate). 1, 2

Genetic Testing Indications

RET genetic testing should be performed in:

• Any patient diagnosed with medullary thyroid carcinoma (MTC)
• Patients with pheochromocytoma, especially if bilateral or diagnosed at young age
• All first-degree relatives of confirmed MEN2 patients (familial mutation testing)
• Patients presenting with clinical features of MEN2B: mucosal neuromas, marfanoid habitus, intestinal ganglioneuromatosis, alacrima 1

MEN2 demonstrates striking genotype-phenotype correlations that directly guide clinical management. The RET proto-oncogene on chromosome 10q11.21 has pathogenic variants primarily in exons 10 and 11 (comprising 95% of MEN2A cases), with the M918T variant in exon 16 being the highest risk mutation associated with MEN2B 1.

Risk Stratification by RET Mutation

ATA Highest Risk (HST)

Mutations: M918T, A883F, compound heterozygous variants

• MTC risk: 100% lifetime risk, presents in infancy
• Pheochromocytoma risk: 50%
• PHPT risk: Does NOT occur with M918T 1, 2

ATA High Risk (H)

Mutations: Codons 609,611,618,620,630,634,804,891

• MTC risk: >95% lifetime risk, presents in adolescence/early adulthood
• Pheochromocytoma risk: 50%
• PHPT risk: 20-30% (highest with codon 634 mutations) 1

ATA Moderate Risk (MOD)

Mutations: All other RET variants (768,790,791,804, and others)

• MTC risk: 10-50% (variant-specific)
• Pheochromocytoma risk: 10-50% (variant-specific)
• PHPT risk: Lower than High risk category 1, 2

Prophylactic Thyroidectomy Timing

For ATA-HST Mutations (M918T, A883F)

Total thyroidectomy with central neck dissection (level VI) should be performed within the first year of life, ideally by a high-volume pediatric thyroid surgeon. 3, 4, 2

This aggressive approach is critical because MEN2B-associated MTC presents in infancy with highly aggressive behavior. Early diagnosis and treatment within the first year dramatically improves potential for surgical cure 1.

For ATA-H Mutations (Codons 634,618,620, etc.)

Total thyroidectomy should be performed before age 5-6 years. 3, 4

The earliest reported MTC presentation for codon 618 mutations is age 7 years, supporting surgery before age 6. For codon 634 mutations (the most common MEN2A mutation), similar timing applies 3.

For ATA-MOD Mutations

Surgery timing is NOT based on age but on calcitonin surveillance results. 2

• Begin annual serum calcitonin monitoring at age 5 years
• Repeat every 6 months if calcitonin approaches upper limit of normal
• Perform thyroidectomy when calcitonin is persistently elevated and increasing, particularly as it approaches or exceeds 20 pg/mL 2
• Surgery may be considered earlier based on patient/family preference

This approach balances the lower MTC penetrance and later onset against surgical risks in young children. Calcitonin levels before age 3-5 years may be physiologically elevated, requiring age-specific reference ranges 2.

Surveillance Protocols

Medullary Thyroid Carcinoma Surveillance

Pre-operative:

• ATA-HST/H: Surgery performed before routine surveillance needed
• ATA-MOD: Annual serum calcitonin from age 5 years 2
• Thyroid ultrasound NOT recommended for routine surveillance (calcitonin is more sensitive), but perform pre-operatively when calcitonin is elevated for surgical planning 2

Post-operative:

• Annual serum calcitonin monitoring
• Thyroid ultrasound only if calcitonin is rising 2

Pheochromocytoma Surveillance

Critical caveat: Always screen for and treat pheochromocytoma BEFORE any thyroid surgery to prevent hypertensive crisis 4.

Surveillance timing by mutation:

• ATA-HST (M918T, A883F): Annual plasma or urine metanephrines from age 11 years, blood pressure at all visits 2
• ATA-H (codon 634, etc.): Annual plasma or urine metanephrines from age 11 years, blood pressure at all visits 2
• ATA-MOD: Annual plasma or urine metanephrines from age 16 years, blood pressure at all visits 2

Pheochromocytomas typically present in the 4th-5th decade but have been reported as early as age 8 years 1. Bilateral pheochromocytomas occur in 10-50% of RET carriers depending on genotype 1.

Primary Hyperparathyroidism Surveillance

Surveillance timing by mutation:

• ATA-HST (M918T): NOT indicated—PHPT does not occur 2
• ATA-H (especially codon 634): Annual serum calcium from age 11 years 2
• ATA-MOD: Annual serum calcium from age 16 years 2

Measure PTH and 25-hydroxyvitamin D only when hypercalcemia is detected, as PTH elevations may precede hypercalcemia but are generally non-actionable in normocalcemic patients 2.

Surgical Management Principles

Thyroid Surgery

• Total thyroidectomy with bilateral central neck dissection (level VI) for all patients with tumors ≥1 cm or bilateral disease 4
• For tumors <1 cm with unilateral disease, total thyroidectomy is recommended; neck dissection can be considered 4
• More extensive lymph node dissection (levels II-V) for primary tumors ≥1 cm or central compartment metastases 4

Pre-operative Protocol for Pheochromocytoma

When pheochromocytoma is present or suspected:

• α-adrenergic blockade (phenoxybenzamine) or α-methyltyrosine
• Forced hydration
• β-adrenergic blockade AFTER α-blockade for tachyarrhythmias
• This prevents hypertensive crisis during surgery and hypotension after tumor removal 4

Parathyroid Management

For concurrent hyperparathyroidism in MEN2A:

• Leave or autotransplant equivalent mass of 1 normal parathyroid gland if multiglandular hyperplasia present
• Consider cryopreservation of resected parathyroid tissue for potential future implantation 4

Family Screening and Genetic Counseling

All first-degree relatives of MEN2 patients must be offered RET genetic testing. 3, 1

Approximately 50% of MEN2B cases occur de novo, making clinical recognition of phenotypic features crucial 1. The identification of RET mutations enables:

• Early diagnosis before clinical tumor development
• Prophylactic surgery with high cure rates
• Prevention of life-threatening complications
• Reduced anxiety through certainty of carrier status 3

Common Pitfalls and Caveats

1. Never perform thyroid surgery without first excluding/treating pheochromocytoma—this can cause fatal hypertensive crisis 4

2. Calcitonin interpretation in young children: Physiologically elevated levels before age 3-5 years require age-specific reference ranges to avoid false positives 2

3. M918T carriers do NOT develop PHPT—unnecessary calcium screening wastes resources 1, 2

4. Codon 634 mutations carry highest risk for pheochromocytoma and PHPT among MEN2A variants—intensify surveillance 1

5. Surgical expertise matters: Refer to high-volume thyroid surgeons, especially for pediatric cases, to minimize complications (hypoparathyroidism, recurrent laryngeal nerve injury) 1, 4

6. Continuity of care is essential: Interruptions in surveillance or treatment (including targeted therapies for advanced disease) significantly worsen outcomes 3

Advanced Disease Management

For locally advanced or metastatic MTC, selective RET inhibitors (selpercatinib, pralsetinib) have demonstrated efficacy in phase II/III trials and represent standard targeted therapy 5, 6. Treatment requires careful monitoring for gastrointestinal side effects and dose adjustments, with emphasis on maintaining continuity of therapy 7.

The key principle: RET mutations drive tumorigenesis (tumor onset and penetrance) but NOT tumor aggressiveness (invasion and metastasis). 8 This reinforces that early detection through genotype-directed surveillance and prompt surgical intervention—rather than mutation type alone—are the primary determinants of reducing morbidity and mortality in MEN2.